PE20010459A1 - Uso de un compuesto calciolitico con un agente antiresorcion - Google Patents
Uso de un compuesto calciolitico con un agente antiresorcionInfo
- Publication number
- PE20010459A1 PE20010459A1 PE2000000756A PE0007562000A PE20010459A1 PE 20010459 A1 PE20010459 A1 PE 20010459A1 PE 2000000756 A PE2000000756 A PE 2000000756A PE 0007562000 A PE0007562000 A PE 0007562000A PE 20010459 A1 PE20010459 A1 PE 20010459A1
- Authority
- PE
- Peru
- Prior art keywords
- phenoxy
- propyl
- hydroxy
- dimethyl
- amine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14677899P | 1999-07-31 | 1999-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20010459A1 true PE20010459A1 (es) | 2001-06-11 |
Family
ID=22518969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000000756A PE20010459A1 (es) | 1999-07-31 | 2000-07-31 | Uso de un compuesto calciolitico con un agente antiresorcion |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1200076A4 (tr) |
JP (1) | JP2003505502A (tr) |
KR (1) | KR20020016928A (tr) |
CN (1) | CN1367687A (tr) |
AU (1) | AU764716B2 (tr) |
BR (1) | BR0012921A (tr) |
CA (1) | CA2380081A1 (tr) |
CO (1) | CO5180628A1 (tr) |
CZ (1) | CZ2002360A3 (tr) |
EC (1) | ECSP003590A (tr) |
HK (1) | HK1046238A1 (tr) |
HU (1) | HUP0202167A3 (tr) |
IL (1) | IL147875A0 (tr) |
MX (1) | MXPA02001204A (tr) |
NO (1) | NO20020466L (tr) |
PE (1) | PE20010459A1 (tr) |
PL (1) | PL353318A1 (tr) |
TR (1) | TR200200278T2 (tr) |
UY (1) | UY26265A1 (tr) |
WO (1) | WO2001008673A1 (tr) |
ZA (1) | ZA200200784B (tr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030018203A1 (en) | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
AR030684A1 (es) * | 2000-01-24 | 2003-09-03 | Smithkline Beecham Corp | Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
TWI316511B (en) | 2002-11-26 | 2009-11-01 | Smithkline Beecham Corp | Calcilytic compounds |
US7205322B2 (en) | 2003-02-12 | 2007-04-17 | Bristol-Myers Squibb Company | Thiazolidine compounds as calcium sensing receptor modulators |
US7265145B2 (en) | 2003-05-28 | 2007-09-04 | Bristol-Myers Squibb Company | Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method |
TW200845956A (en) * | 2006-12-18 | 2008-12-01 | Smithkline Beecham Corp | Calcilytic compounds |
WO2013098588A1 (en) * | 2011-12-27 | 2013-07-04 | Ubaldo Armato | Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies |
GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
CN108420814A (zh) * | 2017-02-15 | 2018-08-21 | 四川大学 | 一种nps-2143用于抗菌的新用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA002984B1 (ru) * | 1996-04-09 | 2002-12-26 | Эн Пи Эс Фармасьютикалз, Инк. | Кальцилитические соединения, фармацевтические композиции и способ скрининга кальцилитических соединений |
MY121054A (en) * | 1998-04-08 | 2005-12-30 | Smithkline Beecham Corp | Calcilytic compounds as calcium receptor antagonists. |
AR014975A1 (es) * | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
-
2000
- 2000-07-28 EC EC2000003590A patent/ECSP003590A/es unknown
- 2000-07-28 CO CO00056902A patent/CO5180628A1/es not_active Application Discontinuation
- 2000-07-31 PL PL00353318A patent/PL353318A1/xx unknown
- 2000-07-31 IL IL14787500A patent/IL147875A0/xx unknown
- 2000-07-31 CA CA002380081A patent/CA2380081A1/en not_active Abandoned
- 2000-07-31 JP JP2001513403A patent/JP2003505502A/ja not_active Withdrawn
- 2000-07-31 EP EP00952319A patent/EP1200076A4/en not_active Withdrawn
- 2000-07-31 MX MXPA02001204A patent/MXPA02001204A/es active IP Right Grant
- 2000-07-31 PE PE2000000756A patent/PE20010459A1/es not_active Application Discontinuation
- 2000-07-31 CN CN00811177A patent/CN1367687A/zh active Pending
- 2000-07-31 UY UY26265A patent/UY26265A1/es not_active Application Discontinuation
- 2000-07-31 WO PCT/US2000/020834 patent/WO2001008673A1/en active Application Filing
- 2000-07-31 BR BR0012921-6A patent/BR0012921A/pt not_active Application Discontinuation
- 2000-07-31 TR TR2002/00278T patent/TR200200278T2/tr unknown
- 2000-07-31 HU HU0202167A patent/HUP0202167A3/hu unknown
- 2000-07-31 KR KR1020027001298A patent/KR20020016928A/ko not_active Application Discontinuation
- 2000-07-31 AU AU65041/00A patent/AU764716B2/en not_active Ceased
- 2000-07-31 CZ CZ2002360A patent/CZ2002360A3/cs unknown
-
2002
- 2002-01-29 ZA ZA200201784A patent/ZA200200784B/xx unknown
- 2002-01-29 NO NO20020466A patent/NO20020466L/no not_active Application Discontinuation
- 2002-10-15 HK HK02107473.9A patent/HK1046238A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP1200076A1 (en) | 2002-05-02 |
BR0012921A (pt) | 2002-06-18 |
NO20020466L (no) | 2002-03-20 |
WO2001008673A1 (en) | 2001-02-08 |
KR20020016928A (ko) | 2002-03-06 |
ZA200200784B (en) | 2003-01-29 |
CO5180628A1 (es) | 2002-07-30 |
AU764716B2 (en) | 2003-08-28 |
MXPA02001204A (es) | 2004-05-21 |
PL353318A1 (en) | 2003-11-17 |
AU6504100A (en) | 2001-02-19 |
HK1046238A1 (zh) | 2003-01-03 |
ECSP003590A (es) | 2002-02-25 |
EP1200076A4 (en) | 2005-02-09 |
CA2380081A1 (en) | 2001-02-08 |
TR200200278T2 (tr) | 2002-06-21 |
IL147875A0 (en) | 2002-08-14 |
NO20020466D0 (no) | 2002-01-29 |
CN1367687A (zh) | 2002-09-04 |
UY26265A1 (es) | 2001-03-16 |
HUP0202167A3 (en) | 2006-07-28 |
JP2003505502A (ja) | 2003-02-12 |
HUP0202167A2 (en) | 2002-10-28 |
CZ2002360A3 (cs) | 2002-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20010459A1 (es) | Uso de un compuesto calciolitico con un agente antiresorcion | |
BR112012002143B8 (pt) | composto para redução dos níveis de hormônio da paratireóide, composição contendo o referido composto e uso do mesmo | |
Cotes et al. | Pulpal tissue reaction to formocresol vs. ferric sulfate in pulpotomized rat teeth. | |
PE20001089A1 (es) | Metodo para incrementar la dureza y resistencia osea | |
GT199800158AA (es) | Agonistas de prostaglandinas y su uso para tratar trastornos oseos | |
ES2116642T3 (es) | Composicion farmaceutica para tratar la osteoporosis que contiene xantohumol. | |
GT199800083A (es) | Agonistas de prostaglandinas. | |
BR0211932A (pt) | Métodos e composições para administração oral de hormÈnio de paratireóide, pth | |
CN105193523A (zh) | 一种踝关节假体 | |
ES2173956T3 (es) | Suelo estabilizante y mezclas agregadas y estructuras. | |
Sone et al. | A small dose of human parathyroid hormone (1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. | |
YU75800A (sh) | Terapeutske kombinacije koje sadrže modulator selektivnog estrogen receptora i paratiroidni hormon | |
PE20001563A1 (es) | Antagonistas del receptor de vitronectina | |
Elsasser et al. | Deficit of trabecular and cortical bone in elderly women with fracture of the femoral neck. | |
Breusch et al. | Effects of the cementing technique on cementing results concerning the coxal end of the femur | |
Aho et al. | Morphology of osteogenesis in bioactive glass interface. | |
Langlais et al. | Weight-bearing early after osteosynthesis of the femoral neck by nail-plate (100 cases) | |
Goh et al. | Pattern of fall and bone mineral density measurement in hip fractures. | |
AR003089A1 (es) | Uso de los derivados de colecalciferol. | |
Orcel et al. | Spontaneous fissures and fractures of the legs in patients with osteoporosis treated with sodium fluoride | |
Karasawa | Cancer therapy using unsealed radioisotopes-the present and future | |
Ream et al. | The effects of fluoride on the periosteal and endosteal surfaces of the rat femur. A scanning electron microscope study. | |
Leong | Medical treatment of osteoporosis--increasing options. | |
Body | Update on treatment of postmenopausal osteoporosis | |
Kim et al. | Prevention of New Vertebral Fractures after Treatment with Risedronate, Alendronate or Calcium Carbonate in Patients with Osteoporotic Compression Fracture Treated with Cement Augmentation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |